Ricin: Current understanding and prospects for an antiricin vaccine

Expert Review of Vaccines

Volumn 4, Issue 2, 2005, Pages 229-237

  Marsden, Catherine J ^a   Smith, Daniel C ^a   Roberts, Lynne M ^a   Lord, J Michael ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Enzymatic activity; Immunization; Ricin; Vaccination

Indexed keywords

ADENINE; ANTIRICIN VACCINE; ANTITOXIN; ASPARTIC ACID; BOTULINUM TOXIN; BREFELDIN A; CYTOTOXIN; EPITOPE; GALACTOSE; GALACTOSYLTRANSFERASE; GLUTAMINE; GLYCOLIPID; GLYCOPROTEIN; GLYCOSIDASE; HISTIDINE; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; IMMUNOTOXIN; LIPOSOME; MICROSPHERE; NEUTRALIZING ANTIBODY; PHENYLALANINE; RIBOSOME INACTIVATING PROTEIN; RICIN; RIVAX; SERINE; TOXOID; UNCLASSIFIED DRUG; VACCINE; ZIDOVUDINE;

AEROSOL; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBODY DETECTION; ANTIBODY PRODUCTION; BIOLOGICAL WARFARE; CELL DEATH; CELL PROTECTION; CLINICAL FEATURE; CLINICAL TRIAL; CRYSTAL STRUCTURE; CYTOPATHOGENIC EFFECT; DIAGNOSTIC TEST; DISULFIDE BOND; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; INTERNALIZATION; MAMMAL CELL; MICROENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REVIEW; SENSITIVITY AND SPECIFICITY; STRUCTURE ANALYSIS; TECHNIQUE; TOXICITY TESTING; TOXIN ANALYSIS; TOXIN STRUCTURE; VACCINATION;

AMINO ACID SEQUENCE; ANTITOXINS; HUMANS; MOLECULAR SEQUENCE DATA; RICIN; VACCINES;

EID: 17144400399     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.4.2.229     Document Type: Review

References (90)

1. Mistry D. Analysis of the fundamentals. Globoil India 2004: The Solvent Extractors Association of India (2004).
2. Gibson J. Investigation of a ricin-containing envelope at a postal facility South Carolina, 2003. Morb. Mortal. Wkly Rep. 52(46), 1129-1131 (2003).
3. BBC News. Terror police find deadly posion (2003).
4. United Nations. Covention on the prohibition of the development, production, stockpiling and use of chimical weapons and on their destruction. Paris, France (1993).
5. Olsnes S, Kozlov JV. Ricin. Toxicon 39(11), 1723-1728 (2001).
6. Lord MJ, Jolliffe NA, Marsden CJ et al. Ricin. Mechanisms of cytotoxicity. Toxicol. Rev. 22(1), 53-64 (2003). Review of the current understanding of ricin structure, function and the intracellular trafficking properties of ricin.
7. Endo Y, Tsurugi K. RNA N-glycosidase activity of ricin A-chain. Mechanism of action of the toxic lectin ricin on eukaryotic ribosomes. J. Biol. Chem. 262(17), 8128-8130 (1987).
8. Endo Y, Tsurugi K. The RNA N-glycosidase activity of ricin A-chain. Nucleic Acids Symp. Ser. 19, 139-142 (1988).
9. Sperti S, Montanaro L, Mattioli A, Stirpe F. Inhibition by ricin of protein synthesis in vitro: 60S ribosomal subunit as the target of the toxin. Biochem. J. 136(3), 813-815 (1973).
10. Nilsson L, Nygard O. The mechanism of the protein-synthesis elongation cycle in eukaryotes. Effect of ricin on the ribosomal interaction with elongation factors. Eur. J. Biochem. 161(1), 111-117 (1986).
11. Montfort W, Villafranca JE, Monzingo AF et al. The three-dimensional structure of ricin at 2.8 A. J. Biol. Chem. 262(11), 5398-5403 (1987).
12. Rutenber E, Robertus JD. Structure of ricin B-chain at 2.5 A resolution. Proteins 10(3), 260-269 (1991).
13. Rutenber E, Katzin BJ, Ernst S et al. Crystallographic refinement of ricin to 2.5 A. Proteins 10(3), 240-250 (1991).
14. Katzin BJ, Collins EJ, Robertus JD. Structure of ricin A-chain at 2.5 A. Proteins 10(3), 251-259 (1991).
15. Mlsna D, Monzingo AF, Katzin BJ, Ernst S, Robertus JD. Structure of recombinant ricin A chain at 2.3 A. Protein Sci. 2(3), 429-435 (1993).
16. Weston SA, Tucker AD, Thatcher DR, Derbyshire DJ, Pauptit RA. X-ray structure of recombinant ricin A-chain at 1.8 A resolution. J. Mol. Biol. 244(4), 410-422 (1994).
17. Schlossman D, Withers D, Welsh P et al. Role of glutamic acid 177 of the ricin toxin A chain in enzymatic inactivation of ribosomes. Mol. Cell. Biol. 9(11), 5012-5021 (1989).
18. Ready MP, Kim Y, Robertus JD. Site-directed mutagenesis of ricin A-chain and implications for the mechanism of action. Proteins 10(3), 270-278 (1991).
19. Kim Y, Mlsna D, Monzingo AF et al. Structure of a ricin mutant showing rescue of activity by a noncatalytic residue. Biochemistry 31(12), 3294-3296 (1992).
20. Chaddock JA, Roberts LM. Mutagenesis and kinetic analysis of the active site Glu177 of ricin A-chain. Protein Eng. 6(4), 425-431 (1993).
21. Day PJ, Ernst SR, Frankel AE et al. Structure and activity of an active site substitution of ricin A chain. Biochemistry 35(34), 11098-11103 (1996).
22. Monzingo AF, Robertus JD. X-ray analysis of substrate analogs in the ricin A-chain active site. J. Mol. Biol. 227(4), 1136-1145 (1992).
23. Kim Y, Robertus JD. Analysis of several key active site residues of ricin A-chain by mutagenesis and x-ray crystallography. Protein Eng. 5(8), 775-779 (1992).
24. Frankel A, Welsh P, Richardson J, Robertus JD. Role of arginine 180 and glutamic acid 177 of ricin toxin A chain in enzymatic inactivation of ribosomes. Mol. Cell Biol. 10(12), 6257-6263 (1990).
25. Lord JM, Roberts LM, Robertus JD. Ricin: structure, mode of action, and some current applications. FASEB J. 8(2), 201-208 (1994).
26. Sandvig K, Grimmer S, Iversen TG et al. Ricin transport into cells: studies of endocytosis and intracellular transport. Int. J. Med. Microbiol. 290(4-5), 415-420 (2000).
27. Foddy L, Hughes RC. Interactions of lectins with normal, swainsonine-treated and ricin-resistant baby hamster kidney (BHK) cells. Carbobydr. Res. 151, 293-304 (1986).
28. Bradley JL, Suva HM, McGuire PM. Depurination of yeast 26S ribosomal RNA by recombinant ricin A chain. Biochem. Biophys. Res. Commun. 149(2), 588-593 (1987).
29. Sandvig K, van Deurs B. Transport of protein toxins into cells: pathways used by ricin, cholera toxin and Shiga toxin. FEBS Lett. 529(1), 49-53 (2002).
30. Sandvig K, van Deurs B. Membrane traffic exploited by protein toxins. Ann. Rev. Cell Dev. Biol. 18, 1-24 (2002).
31. Sandvig K, Spilsberg B, Lauvrak SU et al. Pathways followed by protein toxins into cells. Int. J. Med. Microbiol. 293(7-8), 483-490 (2004).
32. Roberts LM, Smith DC. Ricin: the endoplasmic reticulum connection. Toxicon 44(5), 469-472 (2004).
33. Pelham HR, Roberts LM, Lord JM. Toxin entry: how reversible is the secretory pathway? Trends Cell Biol. 2(7), 183-185 (1992).
34. Lord JM, Roberts LM. Toxin entry: retrograde transport through the secretory pathway. J. Cell Biol. 140(4), 733-736 (1998).
35. Lord JM, Roberts LM. Retrograde transport: going against the flow. Curr. Biol. 8(2), R56-R58 (1998).
36. Simpson JC, Dascher C, Roberts LM, Lord JM, Balch WE. Ricin cytotoxicity is sensitive to recycling between the endoplasmic reticulum and the Golgi complex. J. Biol. Chem. 270(34), 20078-20083 (1995).
37. Yoshida T, Chen CC, Zhang MS, Wu HC. Disruption of the Golgi apparatus by brefeldin A inhibits the cytotoxicity of ricin, modeccin, and Pseudomonas toxin. Exp. Cell Res. 192(2), 389-395 (1991).
38. Sandvig K, Prydz K, Hansen SH, van Deurs B. Ricin transport in brefeldin A-treated cells: correlation between Golgi structure and toxic effect. J. Cell Biol. 115(4), 971-981 (1991).
39. Rapak A, Falnes PO, Olsnes S. Retrograde transport of mutant ricin to the endoplasmic reticulum with subsequent translocation to cytosol. Proc. Natl Acad. Sci. USA 94(8), 3783-3788 (1997).
40. Spooner RA, Watson PD, Marsden CJ et al. Protein disulfide-isomerase reduces ricin to its A and B chains in the endoplasmic reticulum. Biochem. J. 383(2), 285-293 (2004).
41. Argent RH, Roberts LM, Wales R, Robertas JD, Lord JM. Introduction of a disulfide bond into ricin A-chain decreases the cytotoxicity of the ricin holotoxin. J. Biol. Chem. 269(43), 26705-26710 (1994).
42. Wesche J, Rapak A, Olsnes S. Dependence of ricin toxicity on translocation of the toxin A-chain from the endoplasmic reticulum to the cytosol. J. Biol. Chem. 274(48), 34443-34449 (1999).
43. Hazes B, Read RJ. Accumulating evidence suggests that several AB-toxins subvert the endoplasmic reticulum-associated protein degradation pathway to enter target cells. Biochemistry 36(37), 11051-11054 (1997).
44. Decks ED, Cook JP, Day PJ et al. The low lysine content of ricin A chain reduces the risk of proteolytic degradation after translocation from the endoplasmic reticulum to the cytosol. Biochemistry 41(10), 3405-3413 (2002).
45. Argent RH, Parrott AM, Day PJ et al. Ribosome-mediated folding of partially unfolded ricin A-chain. J. Biol. Chem. 275(13), 9263-9269 (2000).
46. Greenfield RA, Brown BR, Hutchins JB et al. Microbiological, biological, and chemical weapons of warfare and terrorism. Am. J. Med. Sci. 323(6), 326-340 (2002).
47. Franz DR, NK Jaax. Ricin Toxin. In: Medical aspects of Chemical and Biological Warfare. Borden Institute, Walter Reed Army Medical Center, Washington DC, USA, 631-642 (1997).
48. Olsnes S, Pihl, A. Toxic lectins and related proteins. In: Molecular Action of Toxins and Viruses. Cohen P, van Heyningen S (Eds). Elsever Biomedical Press, Amsterdam, The Netherlands, 51-105 (1982).
49. Rauber A, Heard J. Castor bean toxicity re-examined: a new perspective. Vet. Hum. Toxicol. 27(6), 498-502 (1985).
50. Ramsden CS, Drayson MT, Bell EB. The toxicity, distribution and excretion of ricin holotoxin in rats. Toxicology 55(1-2), 161-171 (1989).
51. Godal A, Olsnes S, Pihl A. Radioimmunoassays of abrin and ricin in blood. J. Toxicol. Environ. Health 8(3), 409-417(1981).
52. Cmiech HA, Morley M, Gee DJ. Immunocytochemical detection of ricin. I. Preliminary immunofluorescence studies. Histochem. J. 17(8), 859-866 (1985).
53. Griffiths GD, Leith AG, Leek MD, Green MA. Demonstration of ricin within the mammalian para-aortic lymph node. I. Comparison of the localization, after intramuscular injection, with three immunocytochemical methods. Histochem. J. 21(7), 380-386 (1989).
54. Griffiths GD, Leith AG, Leek MD, Green MA. Distribution of ricin within the mammalian para-aortic lymph node. II. Comparison of the localization, after intramuscular dosage of colloidal gold-labelled ricin in vivo, with in vitro binding characteristics of the native toxin. Histochem. J. 21(7), 387-392 (1989).
55. Ligler FS, Taitt CR, Shriver-Lake LC et al. Array biosensor for detection of toxins. Anal. Bioanal. Chem. 377(3), 469-477 (2003).
56. Griffiths GD, Newman H, Gee DJ. Identification and quantification of ricin toxin in animal tissues using ELISA. J. Forensic Sci. Soc. 26(5), 349-358 (1986).
57. Leith AG, Griffiths GD, Green MA. Quantification of ricin toxin using a highly sensitive avidin/biotin enzyme-linked immunosorbent assay. J. Forensic Sci. Soc. 28(4), 227-236 (1988).
58. Poli MA, Rivera VR, Hewetson JF, Merrill GA. Detection of ricin by colorimetric and chemiluminescence ELISA. Toxicon 32(11), 1371-1377 (1994).
59. Shyu HF, Chiao DJ, Liu HW, Tang SS. Monoclonal antibody-based enzyme immunoassay for detection of ricin. Hybrid Hybridomics 21(1), 69-73 (2002).
60. Shyu RH, Shyu HF, Liu HW, Tang SS. Colloidal gold-based immunochromatographic assay for detection of ricin. Toxicon 40(3), 255-258 (2002). Describes a sensitive and rapid immunochomatographic assay that has been developed for the detection of ricin.
61. Thompson WL, Scovill JP, Pace JG. Drugs that show protective effects from ricin toxicity in in vitro protein synthesis assays. Nat. Toxins 3(5), 369-377 (1995).
62. Tanaka KS, Chen XY, Ichikawa Y et al. Ricin A-chain inhibitors resembling the oxacarbenium ion transition state. Biochemistry 40(23), 6845-6851 (2001).
63. Roday S, Amukele T, Evans GB et al. Inhibition of ricin a-chain with pyrrolidine mimics of the oxacarbenium ion transition state. Biochemistry 43(17), 4923-4933 (2004).
64. Miller DJ, Ravikumar K, Shen H et al. Structure-based design and characterization of novel platforms for ricin and shiga toxin inhibition. J. Med. Chem. 45(1), 90-98 (2002).
65. Robertus JD, Yan X, Ernst S et al. Structural analysis of ricin and implications for inhibitor design. Toxicon 34(11-12), 1325-1334 (1996).
66. Yan X, Hollis T, Svinth M et al. Structure-based identification of a ricin inhibitor. J. Mol. Biol. 266(5), 1043-1049 (1997).
67. Hewetson JF, Rivera VR, Creasia DA et al. Protection of mice from inhaled ricin by vaccination with ricin or bypassive treatment with heterologous antibody. Vaccine 11(7), 743-746 (1993).
68. Foxwell BM, Detre SI, Donovan TA, Thorpe PE. The use of antiricin antibodies to protect mice intoxicated with ricin. Toxicology 34(1), 79-88 (1985).
69. Poli MA, Rivera VR, Pitt ML, Vogel P. Aerosolized specific antibody protects mice from lung injury associated with aerosolized ricin exposure. Toxicon 34(9), 1037-1044 (1996).
70. Van C, Rill WL, Malli R et al. Intranasal stimulation of long-lasting immunity against aerosol ricin challenge with ricin toxoid vaccine encapsulated in polymeric microspheres. Vaccine 14(11), 1031-1038 (1996).
71. Griffiths GD, Lindsay CD, Allenby AC et al. Protection against inhalation toxicity of ricin and abrin by immunisation. Hum. Exp. Toxicol. 14(2), 155-164 (1995). Subcutaneous immunization is shown to protect against lethality from inhalation of ricin but does not prevent significant lung damage.
72. Griffiths GD, Bailey SC, Hambrook JL, Keyte MP Local and systemic responses against ricin toxin promoted by toxoid or peptide vaccines alone or in liposomal formulations. Vaccine 16(5), 530-535 (1998).
73. Griffiths GD, Bailey SC, Hambrook JL et al. Liposomally-encapsulated ricin toxoid vaccine delivered intratracheally elicits a good immune response and protects against a lethal pulmonary dose of ricin toxin. Vaccine 15(17-18), 1933-1939 (1997).
74. Kende M, Van C, Hewetson J et al. Oral immunization of mice with ricin toxoid vaccine encapsulated in polymeric microspheres against aerosol challenge. Vaccine 20(11-12), 1681-1691 (2002). An assessment of the advantages of microencapsulated ricin toxoid vaccine over aqueous vaccine for oral immunization.
75. Van C, Rill WL, Malli R et al. Dependence of ricin toxoid vaccine efficacy on the structure of poly(lactide-co-glycolide) microparticle carriers. Vaccine 13(7), 645-651 (1995).
76. Griffiths GD, Phillips GJ, Bailey SC. Comparison of the quality of protection elicited by toxoid and peptide liposomal vaccine formulations against ricin as assessed by markers of inflammation. Vaccine 17(20-21), 2562-2568 (1999). The quality of lung protection by ricin vaccines is assessed following intratracheal challenge by using markers of inflamation.
77. Morris W, Steinhoff MC, Russell PK. Potential of polymer microencapsulation technology for vaccine innovation. Vaccine 12(1), 5-11(1994).
78. Gupta RK, Siber GR. Adjuvants for human vaccines-current status, problems and future prospects. Vaccine 13(14), 1263-1276 (1995).
79. Maddaloni M, Cooke C, Wilkinson R et al. Immunological characteristics associated with the protective efficacy of antibodies to ricin. J. Immunol. 172(10), 6221-6228 (2004).
80. Marsden CJ, Knight S, Smith DC et al. Insertional mutagenesis of ricin A chain: a novel route to an antiricin vaccine. Vaccine 22(21-22), 2800-2805 (2004). A novel vaccine candidate that has been demonsrated to protect animals from ricin intoxication is described.
81. Smallshaw JE, Firan A, Fulmer JR et al. A novel recombinant vaccine which protects mice against ricin intoxication. Vaccine 20(27-28), 3422-3427 (2002). A novel vaccine candidate that has been demonsrated to protect animals from ricin intoxication is described.
82. Smallshaw JE, Ghetie V, Rizo J et al. Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice. Nature Biotechnol. 21(4), 387-391 (2003).
83. Olson MA, Carra JH, Roxas-Duncan V et al. Finding a new vaccine in the ricin protein fold. Protein Engl. Des. Sel. 17(4), 391-397 (2004). A novel vaccine candidate that has been demonsrated to protect animals from ricin intoxication is described.
84. McHugh CA, Tammariello RF, Millard CB, Carra JH. Improved stability of a protein vaccine through elimination of a partially unfolded state. Protein Sci. 13(10), 2736-2743 (2004).
85. Roberts LM, Lord JM. Cytotoxic proteins. Curr. Opin. Biotechnol. 3(4), 422-429 (1992).
86. Soler-Rodriguez AM, Ghetie MA, Oppenheimer-Marks N, Uhr JW, Vitetta ES. Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome. Exp. Cell Res. 206(2), 227-234 (1993).
87. Baluna R, Rizo J, Gordon BE, Ghetie V, Vitetta ES. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc. Natl Acad. Sci. USA 96(7), 3957-3962 (1999).
88. Lebeda FJ, Olson MA. Prediction of a conserved, neutralizing epitope in ribosome-inactivating proteins. Int. J. Biol. Macromol. 24(1), 19-26 (1999).
89. Tommasi M, Castelletti D, Pasti M et al. Identification of ricin A-chain HLA class II-restricted epitopes by human T-cell clones. Clin. Exp. Immunol. 125(3), 391-400 (2001).
90. Castelletti D, Fracasso G, Righetti S et al. A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an antiCD25 immunotoxin. Clin. Exp. Immunol 136(2), 365-372 (2004).